Citadel Advisors’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $20.6M | Sell |
294,496
-195,274
| -40% | -$10.1M | ﹤0.01% | 2542 |
|
|
2026
Q1 | $24.9M | Sell |
489,770
-89,360
| -15% | -$4.17M | ﹤0.01% | 2063 |
|
|
2025
Q4 | $17.1M | Sell |
579,130
-1,408,601
| -71% | -$38.3M | ﹤0.01% | 2548 |
|
|
2025
Q3 | $51.3M | Buy |
1,987,731
+153,023
| +8% | +$4.27M | 0.01% | 1354 |
|
|
2025
Q2 | $50.6M | Buy |
1,834,708
+74,423
| +4% | +$1.96M | 0.01% | 1237 |
|
|
2025
Q1 | $49.9M | Buy |
1,760,285
+988,393
| +128% | +$35.1M | 0.01% | 1146 |
|
|
2024
Q4 | $32.1M | Buy |
771,892
+519,516
| +206% | +$24.8M | 0.01% | 1682 |
|
|
2024
Q3 | $16.9M | Sell |
252,376
-208,080
| -45% | -$19.1M | ﹤0.01% | 2238 |
|
|
2024
Q2 | $54.7M | Buy |
460,456
+188,119
| +69% | +$23.8M | 0.01% | 1082 |
|
|
2024
Q1 | $29M | Sell |
272,337
-268,679
| -50% | -$27.1M | 0.01% | 1696 |
|
|
2023
Q4 | $53.8M | Buy |
541,016
+35,601
| +7% | +$2.99M | 0.01% | 1123 |
|
|
2023
Q3 | $52.2M | Buy |
505,415
+406,060
| +409% | +$45.3M | 0.01% | 1041 |
|
|
2023
Q2 | $12.1M | Sell |
99,355
-123,630
| -55% | -$16.5M | ﹤0.01% | 2431 |
|
|
2023
Q1 | $34.2M | Buy |
222,985
+122,347
| +122% | +$20.2M | 0.01% | 1418 |
|
|
2022
Q4 | $18.1M | Buy |
100,638
+17,061
| +20% | +$2.79M | ﹤0.01% | 2074 |
|
|
2022
Q3 | $9.88M | Sell |
83,577
-7,382
| -8% | -$1.12M | ﹤0.01% | 2787 |
|
|
2022
Q2 | $13M | Buy |
90,959
+70,149
| +337% | +$10M | ﹤0.01% | 2348 |
|
|
2022
Q1 | $3.58M | Sell |
20,810
-498,642
| -96% | -$83.9M | ﹤0.01% | 4827 |
|
|
2021
Q4 | $132M | Buy |
519,452
+243,006
| +88% | +$71.1M | 0.03% | 520 |
|
|
2021
Q3 | $106M | Sell |
276,446
-438,233
| -61% | -$162M | 0.02% | 624 |
|
|
2021
Q2 | $168M | Sell |
714,679
-517,219
| -42% | -$92.4M | 0.04% | 403 |
|
|
2021
Q1 | $161M | Buy |
1,231,898
+146,980
| +14% | +$21.3M | 0.04% | 374 |
|
|
2020
Q4 | $113M | Buy |
1,084,918
+1,068,494
| +6,506% | +$108M | 0.03% | 477 |
|
|
2020
Q3 | $1.16M | Sell |
16,424
-40,077
| -71% | -$2.79M | ﹤0.01% | 5759 |
|
|
2020
Q2 | $3.63M | Buy |
56,501
+46,262
| +452% | +$2.53M | ﹤0.01% | 3543 |
|
|
2020
Q1 | $307K | Sell |
10,239
-85,786
| -89% | -$1.97M | ﹤0.01% | 7303 |
|
|
2019
Q4 | $1.88M | Buy |
96,025
+24,310
| +34% | +$431K | ﹤0.01% | 4513 |
|
|
2019
Q3 | $1.14M | Sell |
71,715
-630,763
| -90% | -$9.32M | ﹤0.01% | 5367 |
|
|
2019
Q2 | $10.3M | Buy |
702,478
+543,370
| +342% | +$11.7M | ﹤0.01% | 2143 |
|
|
2019
Q1 | $3.24M | Buy |
+159,108
| New | +$2.95M | ﹤0.01% | 3632 |
|
Other funds holding MRNA
TP
Citadel Advisors's MRNA Position: Q2 2026 in Review
Citadel Advisors reduced its Moderna (MRNA) stake by 40% in Q2 2026, selling an estimated $10.1M and leaving 294,496 shares worth $20.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2542.
Citadel Advisors first reported a position in MRNA in Q1 2019 and has held it in 30 quarters since. The position peaked at $168M in Q2 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.
- Citadel Advisors held 294,496 shares of Moderna worth $20.6M as of Q2 2026.
- Citadel Advisors sold 195,274 Moderna shares in Q2 2026, an estimated $10.1M.
- Moderna made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2542 holding.
- Citadel Advisors first reported a position in Moderna in Q1 2019 and has held it in 30 quarters since.
- Citadel Advisors's Moderna position peaked at $168M in Q2 2021.
- 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.